文献速递前列腺癌

抗雄激素治疗对COVID-19结局影响的2期试验:无获益证据,并有流行病学与体外数据支持

A Phase 2 Trial of the Effect of Antiandrogen Therapy on COVID-19 Outcome: No Evidence of Benefit, Supported by Epidemiology and In Vitro Data.
PubMed 文献 · Eur Urol · 2021-12-15

COVIDENZA随机2期试验纳入42例住院COVID-19患者,按2:1随机接受恩扎卢胺5天或标准治疗,恩扎卢胺组出院时间延长(HR 0.43,95%CI 0.20-0.93),试验提前终止。基于7894例SARS-CoV-2阳性前列腺癌患者的回顾性研究未观察到预防效果,接受雄激素剥夺治疗(ADT)联合阿比特龙或恩扎卢胺的虚弱患者死于COVID-19风险更高(HR 2.51,95%CI 1.52-4.16)。体外数据显示恩扎卢胺对病毒复制无影响。

要点

  • 恩扎卢胺组出院时间延长(HR 0.43,95%CI 0.20-0.93),试验提前终止。
  • ADT联合阿比特龙或恩扎卢胺的虚弱患者死于COVID-19风险更高(HR 2.51,95%CI 1.52-4.16)。
  • 体外数据显示恩扎卢胺对病毒复制无影响。

核心结论

  • 结果不支持恩扎卢胺的治疗效果或比卡鲁胺或ADT的预防效果。
  • 这些抗雄激素药物不应用于住院COVID-19患者或作为COVID-19预防。
  • 在此背景下进一步研究这些治疗药物没有依据。

研究设计与样本

  • 随机2期临床试验(COVIDENZA)在安全性评估前纳入42例住院COVID-19患者,按2:1随机接受恩扎卢胺5天或标准治疗。
  • 基于人群的回顾性研究纳入7894例SARS-CoV-2阳性前列腺癌患者。
  • 实验研究使用原代肺细胞的气液界面三维培养模型。

主要发现

  • COVIDENZA主要结局为机械通气或出院时间;恩扎卢胺组出院时间延长(HR 0.43,95%CI 0.20-0.93),试验提前终止。
  • 流行病学研究未观察到预防效果;接受ADT联合阿比特龙或恩扎卢胺的虚弱患者死于COVID-19风险更高(HR 2.51,95%CI 1.52-4.16)。
  • 体外数据显示恩扎卢胺对病毒复制无影响。

临床怎么用

  • 作者结论认为这些抗雄激素药物不应用于住院COVID-19患者或作为COVID-19预防。

局限性

  • 流行病学研究存在残余混杂因素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Men are more severely affected by COVID-19. Testosterone may influence SARS-CoV-2 infection and the immune response. OBJECTIVE: To clinically, epidemiologically, and experimentally evaluate the effect of antiandrogens on SARS-CoV-2 infection. DESIGNS, SETTINGS, AND PARTICIPANTS: A randomized phase 2 clinical trial (COVIDENZA) enrolled 42 hospitalized COVID-19 patients before safety evaluation. We also conducted a population-based retrospective study of 7894 SARS-CoV-2-positive prostate cancer patients and an experimental study using an air-liquid interface three-dimensional culture model of primary lung cells. INTERVENTION: In COVIDENZA, patients were randomized 2:1 to 5 d of enzalutamide or standard of care. OUTCOME MEASUREMENTS: The primary outcomes in COVIDENZA were the time to mechanical ventilation or discharge from hospital. The population-based study investigated risk of hospitalization, intensive care, and death from COVID-19 after androgen inhibition. RESULTS AND LIMITATIONS: Enzalutamide-treated patients required longer hospitalization (hazard ratio [HR] for discharge from hospital 0.43, 95% confidence interval [CI] 0.20-0.93) and the trial was terminated early. In the epidemiological study, no preventive effects were observed. The frail population of patients treated with androgen deprivation therapy (ADT) in combination with abiraterone acetate or enzalutamide had a higher risk of dying from COVID-19 (HR 2.51, 95% CI 1.52-4.16). In vitro data showed no effect of enzalutamide on virus replication. The epidemiological study has limitations that include residual confounders. CONCLUSIONS: The results do not support a therapeutic effect of enzalutamide or preventive effects of bicalutamide or ADT in COVID-19. Thus, these antiandrogens should not be used for hospitalized COVID-19 patients or as prevention for COVID-19. Further research on these therapeutics in this setting are not warranted. PATIENT SUMMARY: We studied whether inhibition of testosterone could diminish COVID-19 symptoms. We found no evidence of an effect in a clinical study or in epidemiological or experimental investigations. We conclude that androgen inhibition should not be used for prevention or treatment of COVID-19.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Welén K, Rosendal E, Gisslén M, et al. A Phase 2 Trial of the Effect of Antiandrogen Therapy on COVID-19 Outcome: No Evidence of Benefit, Supported by Epidemiology and In Vitro Data. Eur Urol. 2021. PMID: 34980495. doi:10.1016/j.eururo.2021.12.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。